Antiphospholipid Antibodies and Early Severe Preeclampsia.

This study is not yet open for participant recruitment. (see Contacts and Locations)
Verified June 2013 by Saint Thomas Hospital, Panama
Sponsor:
Information provided by (Responsible Party):
Osvaldo A. Reyes T., Saint Thomas Hospital, Panama
ClinicalTrials.gov Identifier:
NCT01538121
First received: February 19, 2012
Last updated: June 30, 2013
Last verified: June 2013
  Purpose

The Antiphospholipid Syndrome is an immune disease where the presence of antibodies directed against cell membrane phospholipids (antiphospholipid antibodies) can cause an hypercoagulable state that causes thrombosis and obstetric complications (miscarriages, stillbirths). Since 1999 the Sapporo Criteria for Antiphospholipid Syndrome diagnosis includes the development of severe preeclampsia before 34 weeks of gestation, but this was done without solid evidence of a relation between the two. Our study will try to add information to this particular point.


Condition
Severe Preeclampsia
Antiphospholipid Syndrome

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: Antiphospholipid Antibodies and Early Severe Preeclampsia (< 34 Weeks of Gestation). A Case-Control Study.

Resource links provided by NLM:


Further study details as provided by Saint Thomas Hospital, Panama:

Primary Outcome Measures:
  • Lupus anticoagulant [ Time Frame: 15 months ] [ Designated as safety issue: No ]
    Number of cases positive for Lupus Anticoagulant.

  • Anticardiolipin antibodies [ Time Frame: 15 months ] [ Designated as safety issue: No ]
    Number of cases with high/medium levels of IgG/IgM of anticardiolipin antibodies.

  • B2 Glycoprotein I [ Time Frame: 15 months ] [ Designated as safety issue: No ]
    Number of cases with levels of B2 Glycoprotein 1 > 99%


Estimated Enrollment: 310
Study Start Date: August 2013
Estimated Study Completion Date: July 2014
Estimated Primary Completion Date: June 2014 (Final data collection date for primary outcome measure)
Groups/Cohorts
Cases-Early Severe Preeclampsia
Patients with severe preeclampsia before 34 weeks of gestation
Controls
Patients with normal pregnancies at term.

  Eligibility

Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Pregnant patients admitted for severe preeclampsia between 24-34 weeks pf gestation (cases) and normal patients in labor at term (controls).

Criteria

Inclusion Criteria:

  • Gestational age between 24-34 weeks
  • Diagnosis of severe preeclampsia

Exclusion Criteria:

  • Known antiphospholipid syndrome.
  • Known presence of antiphospholipid antibodies.
  • Patients with systemic lupus erythematosus.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01538121

Locations
Panama
Saint Thomas Maternity Hospital
Panama, Panama
Sponsors and Collaborators
Saint Thomas Hospital, Panama
Investigators
Principal Investigator: Osvaldo A Reyes, MD Saint Thomas Hospital, Panama
  More Information

No publications provided

Responsible Party: Osvaldo A. Reyes T., MD, Saint Thomas Hospital, Panama
ClinicalTrials.gov Identifier: NCT01538121     History of Changes
Other Study ID Numbers: MHST2012-01A
Study First Received: February 19, 2012
Last Updated: June 30, 2013
Health Authority: Panama: Ministry of Health

Keywords provided by Saint Thomas Hospital, Panama:
Antibodies, anticardiolipin
Antibodies, B2 Glycoprotein I
Lupus Anticoagulant
Severe Preeclampsia

Additional relevant MeSH terms:
Antiphospholipid Syndrome
Pre-Eclampsia
Hypertension, Pregnancy-Induced
Pregnancy Complications
Autoimmune Diseases
Immune System Diseases
Antibodies
Immunoglobulins
Antibodies, Antiphospholipid
Immunologic Factors
Physiological Effects of Drugs
Pharmacologic Actions

ClinicalTrials.gov processed this record on September 30, 2014